Venlafaxine Hydrochloride
Product Images NDC 50090-5145

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 50090-5145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 01)

This is a drug interaction chart that shows the effects of interacting drugs, including Ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, and Lithium in CYP2D6 EM's and PM's. The chart also includes the analyte Venlafaxine and PK Fold Change and 90% C recommendation for Cmax and AUC. The chart provides recommendations on avoiding concurrent use or using caution while administering the drugs, especially in cases of hypertension, elderly patients, or hepatic dysfunction.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 02)

This text appears to be a table with a list of interacting drugs and analyte PK fold change with recommendations associated with the change. The table lists several drugs, including Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, and Lithium. The recommendations for each drug are listed as "avoid concomitant use," "no dose adjustment," "use with caution," "monitor blood pressure," "no restriction," and "clinical significance unknown." The table also includes information about active moieties, Cmax, Auc, and change relative to the reference value.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 03)

This document contains information regarding dosage recommendations for the drug venlafaxine in individuals with certain medical conditions or genetic polymorphisms. Specific populations are identified as having liver or renal impairment, CYP2D8 polymorphisms, or being over 80 years of age. Dosage adjustments are recommended for those populations. The document also includes analytical information on the drug, including Cmax and AuC data. However, some portions of the text are not decipherable ("ooV" and "ooy") and may represent errors.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (E5d724aa Bc22 4503 B0e0 87b3b1d4a77e 04)

This text seems to be a random combination of letters and a drug name "venlafaxine hydrochloride". It is not possible to generate a useful description with this text as it does not provide any information or context.*

FDA Label Image

Label Image (Lbl500905145)

Product No. 6526-6 is a pack of 30 extended-release capsules containing 75mg of Venlafaxine hydrochloride.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.